Compare Medtronic PLC (MDT) vs Rocket Companies Inc. Class A Common Stock (RKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Rocket Companies Inc. Class A Common Stock — how do they compare? Medtronic PLC trades at $95.24 (market cap $120.53B), while Rocket Companies Inc. Class A Common Stock trades at $10.9 (market cap $29.82B). The key difference: Medtronic PLC is far larger — about 4× Rocket Companies Inc. Class A Common Stock's market cap, and Medtronic PLC pays a 3.06% dividend while Rocket Companies Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Rocket Companies Inc. Class A Common Stock for 0 Days on average.
| MDT | RKT | |
|---|---|---|
Market Cap | $120.53B | $29.82B |
Volume | 49,858,758 | 46,995,062 |
Sector | Health | Financials |
52-Week High | $105.35 | $23.44 |
52-Week Low | $73.75 | $10.53 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $139.87B | $59.81B |
Dividend Yield | 3.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $93.01, up 1.17% with a bullish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 13.93% net margin, and positive cash flow trends. Recent regulatory approvals for medical devices and a 49-year dividend growth streak support investor confidence. Analyst consensus is strongly bullish with 60.78% buy ratings and a $97.73 price target, suggesting 5% upside potential from current levels.
MDT offers stable growth with raised revenue guidance and dividend reliability, though debt levels have increased to 31.11% of assets. Key risks include competitive pressures in medical devices and market volatility. The stock remains attractive for income investors seeking healthcare exposure with consistent performance and analyst support.
Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.
Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Rocket Companies Inc. Class A Common Stock
Rocket Companies, Inc. operates a homeownership platform spanning mortgage origination and servicing, real estate, title and closing, and personal finance, with flagship brands including Rocket Mortgage, Rocket Close, Rocket Money, Rocket Loans, and Redfin.
Read more on RKT →
